Nacerfin (Solifenacin Succinate)

Solifenacin succinate is used to manage symptoms of overactive bladder and related urinary disorders.

• Overactive bladder: increases functional bladder capacity and reduces the number of urgency episodes per day.
• Urge urinary incontinence: lessens involuntary urine leakage by decreasing detrusor overactivity.
• Urinary frequency: lowers the number of daytime voids, improving daily comfort.
• Urinary urgency: diminishes the sudden, strong urge to void, helping patients regain control.
• Nocturia: may reduce nighttime urinary episodes, improving sleep quality.

• Solifenacin succinate acts as a competitive antagonist at muscarinic M3 receptors located on the bladder detrusor muscle. By blocking these receptors, it inhibits acetylcholine‑mediated contractions, thereby reducing involuntary detrusor activity, increasing bladder storage capacity, and alleviating symptoms of urgency, frequency and urge incontinence. The selectivity for M3 over other muscarinic subtypes helps limit systemic anticholinergic effects, while its long half‑life supports once‑daily dosing.

Solifenacin succinate may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Dry mouth: reduced salivary secretion causing thirst.
• Constipation: slowed gastrointestinal motility.
• Blurred vision: transient visual disturbances.
• Urinary retention: difficulty initiating or completing voiding.
• Headache: mild to moderate head pain.
• Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects

• Severe urinary retention: may require catheterisation.
• Allergic reactions: rash, pruritus, angioedema or anaphylaxis.
• Tachycardia: rapid heart rate potentially needing medical attention.
• QT interval prolongation: risk of cardiac arrhythmias.
• Acute angle‑closure glaucoma: sudden eye pain and visual loss.
• Hepatic enzyme elevation: abnormal liver function tests.

When prescribing solifenacin succinate, clinicians should consider several safety precautions to minimise risk.

• Renal impairment: assess kidney function and adjust dose if necessary.
• Hepatic impairment: use with caution in patients with liver disease.
• Narrow‑angle glaucoma: contraindicated due to anticholinergic effect on intra‑ocular pressure.
• Elderly patients: monitor for urinary retention and constipation.
• Pregnancy: safety not established; avoid unless benefit outweighs risk.
• Store at room temperature: keep in original packaging, protect from moisture and heat.

Solifenacin succinate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase solifenacin exposure.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect.
• Concurrent anticholinergic agents: additive anticholinergic burden increasing side effects.

Moderate Interactions (Monitor Closely)

• Digoxin: solifenacin may increase serum digoxin levels.
• Antidiabetic drugs (e.g., insulin, sulfonylureas): monitor blood glucose as solifenacin may affect glycemic control.
• Antihistamines (e.g., diphenhydramine): may enhance anticholinergic effects.